Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Bioventus Inc.NASDAQ: BVS
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows in line with its trailing trend
Q1 FY2026 cost of revenue of $42.43M rose 0.0% year over year, in line with the -0.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 15.8% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Cost of revenue amounted to 32.7% of revenue in FY2025, up 0.4 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of -0.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 185.66M USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- +9.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.66M | +0.3% |
| FY2024 | 2024-12-31 | 185.05M | +0.5% |
| FY2023 | 2023-12-31 | 184.15M | +1.7% |
| FY2022 | 2022-12-31 | 181.04M | +41.2% |
| FY2021 | 2021-12-31 | 128.19M | — |
Cost of Revenue vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 cost of revenue of $185.67M is the 4th highest of the 9 companies compared; the peer median is $112.88M.
- Its year-over-year change of -0.4% is the 7th highest of 9, against a peer median of +8.7%.
- Cost of revenue amounts to 32.2% of revenue for BVS, versus a peer median of 32.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $1.96B | +13.1% | +8.9% | 31.7% | |
| LTM Mar 2026 | $769.47M | +2.0% | +10.4% | 46.8% | |
| LTM Mar 2026 | $255.74M | -3.2% | +29.9% | 31.0% | |
| LTM Mar 2026 | $185.67M | -0.4% | +0.8% | 32.2% | |
| LTM Mar 2026 | $151.94M | +37.2% | +9.4% | 29.6% | |
| LTM Mar 2026 | $73.82M | +15.6% | +14.8% | 19.0% | |
| LTM Mar 2026 | $48.14M | +36.8% | +6.5% | 41.4% | |
| LTM Mar 2026 | $45.91M | -10.2% | +24.3% | 37.7% | |
| LTM Jun 2026 | $25.72M | +4.4% | +21.7% | 32.2% | |
| Peer median (excluding BVS) | $112.88M | +8.7% | +12.6% | 32.0% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M |
| Cost of Revenue | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M |
| Gross Profit | 302.71M | 331.08M | 328.19M | 388.23M | 382.43M |
| Gross Margin | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| Research & Development | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M |
| Selling, General & Admin | 254.25M | 332.13M | 303.88M | 327.09M | 311.77M |
| Operating Expenses | 290.65M | 498.31M | 409.92M | 400.21M | 323.88M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| EBITDA | 45.48M | (121.61M) | (23.07M) | 39.22M | 99.21M |
| EBITDA Margin | 10.6% | -23.7% | -4.5% | 6.8% | 17.5% |
| Operating Income | 12.06M | (167.23M) | (81.73M) | (11.98M) | 58.55M |
| Operating Margin | 2.8% | -32.7% | -16.0% | -2.1% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M |
| Other Income / Expenses | (2.57M) | (21.79M) | (39.39M) | (37.15M) | (32.84M) |
| Income Before Tax | 9.49M | (189.03M) | (121.11M) | (49.13M) | 25.71M |
| Pre-Tax Margin | 2.2% | -36.9% | -23.6% | -8.6% | 4.5% |
| Income Tax Expense | (1.97M) | (44.37M) | 85K | (5.29M) | (1.57M) |
| Net Income | 19.38M | (158.7M) | (156.23M) | (33.54M) | 22.73M |
| Net Margin | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (Basic) | (0.15) | (2.59) | (2.49) | (0.52) | 0.34 |
| EPS (Diluted) | (0.15) | (2.59) | (2.49) | (0.52) | 0.33 |
| Weighted Avg Shares | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M |
| Weighted Avg Shares (Diluted) | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.